Adoptive T cell immunotherapy is an important cancer treatment strategy in which genetically modified T cells are made tumour-specific and activated via introduction of a transgenic antigen receptor, which improves their ability to recognise and destroy tumours. When assessing the efficacy of engineered transgenic T cell receptor (TCR) constructs it is desirable to use cellular reporter systems devoid of endogenous TCR expression. This talk will describe the development of a novel TCR αβ KO (knockout) T Cell Activation Bioassay based on the use of a genetically engineered Jurkat T cell line with endogenous TCR α and β chains knocked out using CRISPR/Cas9. Data will be presented to demonstrate that activation of transgenic TCR-expressing TCRαβ-KO Cells by cognate peptide and major histocompatibility complex (MHC)-expressing antigen-presenting cells (APCs) results in potent TCR activation and promoter-mediated luminescence. For functional assessment of engineered or primary CD8+ T cells a new homogenous immunoassay detection platform for direct ‘in-well’ IL-2 and IFN-γ measurement will also be described in addition to a recently introduced microplate-based target cell killing assay for T-Cell Dependent Cytotoxicity (TDCC) and engineered CAR-T cell killing assays in mixed co-cultures.
The European Laboratory Research & Innovation Group
Our Vision : To provide outstanding, leading edge knowledge to the life sciences community on an open access basis
Get the App
Get this event information on your mobile by going to the Apple or Google Store and search for 'myEventflo'